混合菌根的开发,以提高芬雷丁胺的表面溶解度和抗癌活性,对抗神经母细胞瘤细胞
Guendalina Zuccari1, Alessia Zorzoli2, Danilo Marimpietri2
1Department of Pharmacy, University of Genoa, Viale Benedetto XV 16132 Genoa, Italy.
Current drug delivery
|September 4, 2024
概括
混合小粒有效封装芬雷丁胺 (4-HPR),增强其可溶性和抗癌活性对神经母细胞瘤细胞. 这种配方显示出作为辅助疗法的前景.
科学领域:
- 制药科学 制药科学
- 纳米技术 纳米技术
- 在瘤学瘤学.
背景情况:
- 芬雷丁胺 (4-HPR) 是一种有前途的抗癌药物,具有较差的水溶性.
- 开发有效的药物输送系统对于增强4-HPR的治疗潜力至关重要.
- 混合微粒为难溶性药物提供潜在的纳米载体系统.
研究的目的:
- 为了评估由D-α-托科菲尔聚乙烯甘醇糖酸盐 (TPGS) 和DSPE-PEG组成的混合小粒,用于封装芬雷丁尼德 (4-HPR).
- 为了评估4-HPR加载混合小粒的稳定性,物理化学性质和体外疗效.
主要方法:
- 使用溶剂造技术制备了米塞尔,使用不同的4-HPR:TPGS:DSPE-PEG比率.
- 特性包括颗粒大小,Z-潜力,封装效率 (EE%) 和药物负载 (DL%).
- 在体外细胞毒性使用MTT测定对神经母细胞瘤细胞系进行了评估.
主要成果:
- 配制的小粒体的平均直径为12纳米,封装效率高 (88%),表面溶解率增加了363倍.
- 带有4-HPR的菌体表现出稳定性和缓释特征.
- 与自由4-HPR相比,封装的4-HPR对SK-N-BE-2C神经母细胞瘤细胞显著增强了细胞毒性.
结论:
- 混合是雷丁尼德 (4-HPR) 的一个合适的输送系统.
- 这种配方增强了4-HPR的可溶性和体外疗效.
- 负载细胞代表了神经母细胞瘤治疗的潜在辅助疗法.
相关概念视频
01:16Bioavailability Enhancement: Drug Solubility Enhancement
Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
01:27Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...